<DOC>
	<DOCNO>NCT02755142</DOCNO>
	<brief_summary>This study plan detect dose-efficacy relationship choose dose level MC506/1 extent quality fluorescence tumour core patient newly diagnose malignant glioma .</brief_summary>
	<brief_title>Clinical Study 5-aminolevulinic Acid Hydrochloride ( 5-ALA ) Fluorescence-guided Resection Malignant Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Radiological suspicion malignant glioma distinct ring garland shape , contrast agentenhancing tumour structure core area reduce intensity MRI ( tumour necrosis ) Indication surgical tumour resection First operation tumour , tumourspecific pretreatment Karnofsky Performance Scale 70 % Patient 's write informed consent Age 1875 year Porphyria , hypersensitivity porphyrin Renal insufficiency : Creatinine &gt; 2.0 mg/dl Hepatic insufficiency : Bilirubin &gt; 3 mg/dl Quick test &lt; 60 % GT &gt; 100 U/I Other know malignancy ( except basaliomas ) Women : Existing/planned pregnancy ( checked pregnancy test childbearing age ) /lactation inadequate contraception ( hormone cycle regulation pill condom ) Men : Inadequate contraception ( condom ) Dementia mental condition make impossible understand therapy therefore prohibit write consent Simultaneous participation participation another clinical trial precede 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>